"Leclaza’s mOS data of 38.9 months is remarkable"
By Kim, Jin-Gu | translator Alice Kang
22.07.01 18:22:13
가나다라
0
Professor Ji-Youn Han, Head of Center for Lung Cancer, National Cancer Center (Department of Hemato-oncology)
“Comparable to osimertinib’s results…low rate of adverse events an advantage”
“New methods of treatments pour in in the field of lung cancer… patients do not need to be discouraged”
“The fact that Leclaza (lasertinib) achieved an OS (overall survival) of over 3 years is remarkable.”
New OS data on the homegrown novel lung cancer drug Leclaza that was presented at the AOS 2022 & KCA Annual Meeting 2022 that was held recently in Seoul drew the pharmaceutical industry's attention.
The results were from a trial that evaluated the efficacy and safety of continuous daily oral administration of Leclaza 240mg on 78 adult patients with EGFR mutation-positive NSCLC whose disease had progressed after EGFR TKI that was conducted in 17 centers in Korea. Analysis results on the 76 EGFR T790M mutation-positive patients showed that the median overall survival (mOS) was 38.9 months
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)